featured
Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Triple Class–Exposed/Refractory Relapsed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Blood Cancer J 2024 Sep 11;14(1)155, A McCurdy, D Reece, ML Louzada, D White, S Parkin, MP Chu, R Kotb, H Mian, I Othman, J Su, A Khan, E Gul, S TrudelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.